ACUTAAS Chemicals Reports Strong Q1 FY26 Results, MD Targets 25% Growth for FY26
ACUTAAS Chemicals Limited reported robust Q1 FY26 financial results with significant growth across key metrics. Revenue from operations increased by 17.3% to ₹2,072.00 crore, EBITDA grew by 72.4% to ₹509.00 crore, and net profit surged by 199.6% to ₹440.00 crore. The company's pharmaceutical intermediates business was the primary growth driver. Both pharmaceutical facilities received PMDA GMP certification. ACUTAAS entered a joint venture in South Korea to strengthen its position in the semiconductor market. The company's Managing Director expressed confidence in achieving 25% growth with improved margins for FY26.
*this image is generated using AI for illustrative purposes only.
Acutaas Chemicals Limited (formerly known as Ami Organics Limited) has reported robust financial results for the first quarter of fiscal year 2026, showcasing significant growth and improved profitability. The company's Managing Director has expressed confidence in achieving 25% growth with better margins for the full fiscal year.
Q1 FY26 Financial Highlights
ACUTAAS Chemicals reported impressive year-on-year growth in its Q1 FY26 results:
| Metric | Q1 FY26 | YoY Growth |
|---|---|---|
| Revenue from operations | ₹2,072.00 crore | 17.3% |
| EBITDA | ₹509.00 crore | 72.4% |
| EBITDA margin | 24.6% | 785 bps |
| Net profit (PAT) | ₹440.00 crore | 199.6% |
| PAT margin | 21.2% | 1,290 bps |
Strong Performance in Pharmaceutical Intermediates
The company's growth was primarily driven by robust performance in its Pharmaceutical Intermediates business. This segment has been a key contributor to ACUTAAS Chemicals' overall revenue growth.
Global Compliance and Quality Certification
ACUTAAS Chemicals has achieved an important milestone in its quality assurance efforts. Both of the company's pharmaceutical facilities have now received PMDA GMP certification, underscoring its commitment to global compliance and quality standards.
Strategic Expansion into South Korea
In a significant move to strengthen its position in the semiconductor market, ACUTAAS Chemicals has entered into a joint venture in South Korea. This strategic partnership is expected to bring the company closer to key semiconductor markets and enhance its portfolio with differentiated, high-value products tailored for this space.
Management Commentary
Mr. Naresh Patel, Executive Chairman & Managing Director of ACUTAAS Chemicals Limited, commented on the results: "I am happy to share that we've had a strong start to FY26, with Q1 revenue growing 17.3% year-on-year, driven by robust performance in our Pharmaceutical Intermediates business. With rising customer engagement across CDMO, battery chemicals, and semiconductors, we step into FY26 with strong momentum and confidence to deliver 25% growth with improved margins."
Future Outlook
The company's leadership appears optimistic about the business outlook and margin improvement prospects for FY26. With its strategic initiatives in place, including the South Korean joint venture and increased focus on high-value products, ACUTAAS Chemicals is well-positioned to capitalize on growth opportunities in the specialty chemicals sector.
ACUTAAS Chemicals continues to demonstrate its ability to adapt and grow in the dynamic specialty chemicals market, with a clear focus on pharmaceutical intermediates, semiconductors, and battery chemicals. As the company moves forward with its expansion plans and operational improvements, investors and industry observers will be keenly watching its progress towards achieving the targeted 25% growth for FY26.
